Shares of PLx Pharma Inc (NASDAQ:PLXP) have earned a consensus rating of “Hold” from the five analysts that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $13.00.
A number of brokerages have recently commented on PLXP. ValuEngine raised shares of PLx Pharma from a “strong sell” rating to a “sell” rating in a research report on Monday, December 4th. Zacks Investment Research lowered shares of PLx Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th. Finally, Janney Montgomery Scott began coverage on shares of PLx Pharma in a research report on Friday, January 19th. They issued a “buy” rating and a $14.00 price objective on the stock.
PLx Pharma (NASDAQ PLXP) opened at $6.25 on Tuesday. The company has a quick ratio of 8.88, a current ratio of 8.99 and a debt-to-equity ratio of 0.56. PLx Pharma has a one year low of $5.60 and a one year high of $12.80.
PLx Pharma Company Profile
PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.
Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.